Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where authors phrase all words ' Kirkwood, JM' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 76 riferimenti
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Esche, C; Shurin, GV; Kirkwood, JM; Wang, GQ; Rabinowich, H; Pirtskhalaishvili, G; Shurin, MR
      Tumor necrosis factor-alpha-promoted expression of Bcl-2 and inhibition ofmitochondrial cytochrome c release mediate resistance of mature dendritic cells to melanoma-induced apoptosis

      CLINICAL CANCER RESEARCH
    2. Kirkwood, JM; Ibrahim, JG; Sosman, JA; Sondak, VK; Agarwala, SS; Ernstoff, MS; Rao, U
      High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: Results of Intergroup trial E1694/S9512/C509801

      JOURNAL OF CLINICAL ONCOLOGY
    3. Kirkwood, JM; Ibrahim, J; Lowson, DH; Aikins, MB; Agarwala, SS; Collins, K; Mascari, R; Morrissey, DM; Chapman, PB
      High-dose interferon alfa-2b does mot diminish antibody response to GM2 vaccination in patients with resected melanoma: Results of the multicenter Eastern Cooperative Oncology Group phase II trial E2696

      JOURNAL OF CLINICAL ONCOLOGY
    4. Kirkwood, JM
      Adjuvant therapy of melanoma: At what cost? In reply

      JOURNAL OF CLINICAL ONCOLOGY
    5. Kilbridge, KL; Weeks, JC; Sober, AJ; Haluska, FG; Slingluff, CL; Atkins, MB; Sock, DE; Kirkwood, JM; Nease, RF
      Patient preferences for adjuvant interferon alfa-2b treatment

      JOURNAL OF CLINICAL ONCOLOGY
    6. Kirkwood, JM; Ibrahim, J; Manola, J
      High-dose interferon versus GM2 vaccine in high-risk malignant melanoma - Reply

      JOURNAL OF CLINICAL ONCOLOGY
    7. van Londen, GJ; Mascarenhas, B; Kirkwood, JM
      Rhabdomyolysis, when observed with high-dose interferon-alfa (HDI) therapy, does not always exclude resumption of HDI

      JOURNAL OF CLINICAL ONCOLOGY
    8. Balch, CM; Soong, SJ; Gershenwald, JE; Thompson, JF; Reintgen, DS; Cascinelli, N; Urist, M; McMasters, KM; Ross, MI; Kirkwood, JM; Atkins, MB; Thompson, JA; Coit, DG; Byrd, D; Desmond, R; Zhang, YT; Liu, PY; Lyman, GH; Morabito, A
      Prognostic factors analysis of 17,600 melanoma patients: Validation of theAmerican Joint Committee on Cancer melanoma staging system

      JOURNAL OF CLINICAL ONCOLOGY
    9. Balch, CM; Buzaid, AC; Soong, SJ; Atkins, MB; Cascinelli, N; Coit, DG; Fleming, ID; Gershenwald, JE; Houghton, A; Kirkwood, JM; McMasters, KM; Mihm, MF; Morton, DL; Reintgen, DS; Ross, MI; Sober, A; Thompson, JA; Thompson, JF
      Final version of the American Joint Committee on Cancer staging system forcutaneous melanoma

      JOURNAL OF CLINICAL ONCOLOGY
    10. Hillner, BE; Kirkwood, JM; Agarwala, SS
      Burden of illness associated with metastatic melanoma - An audit of 100 consecutive referral center cases

      CANCER
    11. Agarwala, SS; Kirkwood, JM; Bryant, J
      Phase I, randomized, double-blind trial of 7-allyl-8-oxoguanosine (loxoribine) in advanced cancer

      CYTOKINES CELLULAR & MOLECULAR THERAPY
    12. Leaf, AN; Wolf, BC; Kirkwood, JM; Haselow, RE
      Phase II study of etoposide (VP-16) in patients with thyroid cancer with no prior chemotherapy: an Eastern Cooperative Oncology Group Study (E1385)

      MEDICAL ONCOLOGY
    13. Lotze, MT; Shurin, M; Esche, C; Tahara, H; Storkus, W; Kirkwood, JM; Whiteside, TL; Elder, EM; Okada, H; Robbins, P
      Interleukin-2: Developing additional cytokine gene therapies using fibroblasts or dendritic cells to enhance tumor immunity

      CANCER JOURNAL FROM SCIENTIFIC AMERICAN
    14. Lawson, D; Kirkwood, JM
      Granulocyte-macrophage colony-stimulating factor: Another cytokine with adjuvant therapeutic benefit in melanoma?

      JOURNAL OF CLINICAL ONCOLOGY
    15. Kirkwood, JM; Ibrahim, JG; Sondak, VK; Richards, J; Flaherty, LE; Ernstoff, MS; Smith, TJ; Rao, U; Steele, M; Blum, RH
      High- and low-dose interferon alfa-2b in high-risk melanoma: First analysis of Intergroup Trial E1690/S9111/C9190

      JOURNAL OF CLINICAL ONCOLOGY
    16. Edington, H; Agarwala, S; Kirkwood, JM
      Biologic therapy

      CLINICS IN PLASTIC SURGERY
    17. Zarour, HM; Kirkwood, JM; Kierstead, LS; Herr, W; Brusic, V; Slingluff, CL; Sidney, J; Sette, A; Storkus, WJ
      Melan-A/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitoperecognized by melanoma-reactive CD4(+) T cells

      PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
    18. Zarour, HM; Storkus, WJ; Brusic, V; Williams, E; Kirkwood, JM
      NY-ESO-1 encodes DRB1*0401-restricted epitopes recognized by melanoma-reactive CD4+T cells

      CANCER RESEARCH
    19. Balch, CM; Buzaid, AC; Atkins, MB; Cascinelli, N; Coit, DG; Fleming, ID; Houghton, A; Kirkwood, JM; Mihm, MF; Morton, DL; Reintgen, D; Ross, MI; Sober, A; Soong, SJ; Thompson, JA; Thompson, JF; Gershenwald, JE; McMasters, KM
      A new American Joint Committee on Cancer staging system for cutaneous melanoma

      CANCER
    20. Kirkwood, JM; Mascari, RA; Edington, RD; Rabkin, MS; Day, RS; Whiteside, TL; Vlock, DR; Shipe-Spotloe, JM
      Analysis of therapeutic and immunologic effects of R-24 anti-GD3 monoclonal antibody in 37 patients with metastatic melanoma

      CANCER
    21. Kirkwood, JM
      Adjuvant interferon in the treatment of melanoma

      BRITISH JOURNAL OF CANCER
    22. Agarawala, SS; Kirkwood, JM
      Adjuvant therapy of melanoma

      STRATEGIES IN ADJUVANT THERAPY
    23. Agarwala, SS; Kirkwood, JM
      Melanoma - Immunotherapeutic approaches

      BIODRUGS
    24. Yang, P; Farkas, DL; Kirkwood, JM; Abernethy, JL; Edington, HD; Becker, D
      Macroscopic spectral imaging and gene expression analysis of the early stages of melanoma

      MOLECULAR MEDICINE
    25. Kirkwood, JM; Farkas, DL; Chakraborty, A; Dyer, KF; Tweardy, DJ; Abernethy, JL; Edington, HD; Donnelly, SS; Becker, D
      Systemic interferon-alpha (IFN-alpha) treatment leads to Stat3 inactivation in melanoma precursor lesions

      MOLECULAR MEDICINE
    26. Chapman, PB; Einhorn, LH; Meyers, ML; Saxman, S; Destro, AN; Panageas, KS; Begg, CB; Agarwala, SS; Schuchter, LM; Ernstoff, MS; Houghton, AN; Kirkwood, JM
      Phase III multicenter randomized trial of the dartmouth regimen versus dacarbazine in patients with metastatic melanoma

      JOURNAL OF CLINICAL ONCOLOGY
    27. Tester, WJ; Kim, KM; Krigel, RL; Bonomi, PD; Glick, JH; Asbury, RF; Kirkwood, JM; Blum, RH; Schiller, JH
      A randomized Phase II study of interleukin-2 with and without beta-interferon for patients with advanced non-small cell lung cancer - An Eastern Cooperative Oncology Group study (PZ586)

      LUNG CANCER
    28. Agarwala, SS; Ferri, W; Gooding, W; Kirkwood, JM
      A phase III randomized trial of dacarbazine and carboplatin with and without tamoxifen in the treatment of patients with metastatic melanoma

      CANCER
    29. AGARWALA SS; KIRKWOOD JM
      ADJUVANT THERAPY OF MELANOMA

      Seminars in surgical oncology
    30. KIRKWOOD JM; BROWN IW
      EFFECT OF LIMB DAMAGE ON THE SURVIVAL AND BURIAL TIME OF DISCARDED SPANNER CRABS RANINA-RANINA (LINNAEUS)

      Marine and freshwater research
    31. EGGERMONT AMM; KIRKWOOD JM
      MALIGNANT-MELANOMA - CURRENT CONTROVERSIES, FUTURE PERSPECTIVES - PROCEEDINGS OF A SYMPOSIUM HELD 27-28 FEBRUARY 1997, BARCELONA, SPAIN - INTRODUCTION

      European journal of cancer
    32. KIRKWOOD JM
      SYSTEMIC ADJUVANT TREATMENT OF HIGH-RISK MELANOMA - THE ROLE OF INTERFERON-ALPHA-2B AND OTHER IMMUNOTHERAPIES

      European journal of cancer
    33. AGARWALA SS; REYDERMAN A; STATKEVICH P; FRAASS U; LOOMBA A; STOVER LL; KIRKWOOD JM
      PHARMACOKINETIC STUDY OF TEMOZOLOMIDE PENETRATION INTO CSF IN A PATIENT WITH DURAL MELANOMA

      Annals of oncology
    34. AGARWALA SS; KIRKWOOD JM
      ADJUVANT INTERFERON TREATMENT FOR MELANOMA

      Hematology/oncology clinics of North America
    35. RANIERI E; GESUALDO L; HERR W; GAMBOTTO A; LOGAN T; ZAROUR H; KIRKWOOD JM; STORKUS WJ
      DC-BASED IMMUNIZING STRATEGIES TO PROMOTE ANTIRENAL CANCER T-CELL RESPONSE

      Journal of leukocyte biology
    36. FALKSON CI; IBRAHIM J; KIRKWOOD JM; COATES AS; ATKINS MB; BLUM RH
      PHASE-III TRIAL OF DACARBAZINE VERSUS DACARBAZINE WITH INTERFERON-ALPHA-2B VERSUS DACARBAZINE WITH TAMOXIFEN VERSUS DACARBAZINE WITH INTERFERON-ALPHA-2B AND TAMOXIFEN IN PATIENTS WITH METASTATIC MALIGNANT-MELANOMA - AN EASTERN-COOPERATIVE-ONCOLOGY-GROUP STUDY

      Journal of clinical oncology
    37. COLE BF; GELBER RD; KIRKWOOD JM
      SURVIVAL BENEFIT IN MELANOMA

      Journal of clinical oncology
    38. MORI Y; KONDZIOLKA D; FLICKINGER JC; KIRKWOOD JM; AGARWALA S; LUNSFORD LD
      STEREOTACTIC RADIOSURGERY FOR CEREBRAL METASTATIC MELANOMA - FACTORS AFFECTING LOCAL DISEASE-CONTROL AND SURVIVAL

      International journal of radiation oncology, biology, physics
    39. KIRKWOOD JM
      ADJUVANT IFN-ALPHA-2 THERAPY OF MELANOMA

      Lancet
    40. Logan, TF; Banner, B; Rao, U; Ernstoff, MS; Wolmark, N; Whiteside, TL; Miketic, L; Kirkwood, JM
      Inflammatory cell infiltrate in a responding metastatic nodule after vaccine-based immunotherapy

      CLINICAL AND EXPERIMENTAL IMMUNOLOGY
    41. LOGAN TF; GOODING WE; WHITESIDE TL; ERNSTOFF MS; KAPLAN SS; MIKETIC L; VLOCK DR; TOMPKINS C; WOOD DL; NADLER PI; KIRKWOOD JM
      BIOLOGIC RESPONSE MODULATION BY TUMOR-NECROSIS-FACTOR-ALPHA (TNF-ALPHA) IN A PHASE IB TRIAL IN CANCER-PATIENTS

      Journal of immunotherapy with emphasis on tumor immunology
    42. KIRKWOOD JM; BRYANT J; SCHILLER JH; OKEN MM; BORDEN EC; WHITESIDE TL
      IMMUNOMODULATORY FUNCTION OF INTERFERON-GAMMA IN PATIENTS WITH METASTATIC MELANOMA - RESULTS OF A PHASE II-B TRIAL IN SUBJECTS WITH METASTATIC MELANOMA, ECOG STUDY E-4987

      Journal of immunotherapy with emphasis on tumor immunology
    43. HILLNER BE; KIRKWOOD JM
      ECONOMIC-ANALYSES OF BENEFIT FROM INTERFERON-ALPHA-2B IN HIGH-RISK MELANOMA - TRADE-OFFS BETWEEN COMPLETENESS, SIMPLICITY AND CLARITY

      European journal of cancer
    44. HILLNER BE; KIRKWOOD JM; ATKINS MB; JOHNSON ER; SMITH TJ
      ECONOMIC-ANALYSIS OF ADJUVANT INTERFERON-ALFA 2B (IFN) IN HIGH-RISK MELANOMA USING PROJECTIONS FROM ECOG (E)-1684

      European journal of cancer
    45. HILLNER BE; KIRKWOOD JM; ATKINS MB; JOHNSON ER; SMITH TJ
      ECONOMIC-ANALYSIS OF ADJUVANT INTERFERON ALFA-2B IN HIGH-RISK MELANOMA BASED ON PROJECTIONS FROM EASTERN-COOPERATIVE-ONCOLOGY-GROUP-1684

      Journal of clinical oncology
    46. EDWARDS RP; GOODING W; LEMBERSKY BC; COLONELLO K; HAMMOND R; PARADISE C; KOWAL CD; KUNSCHNER AJ; BALDISSERI M; KIRKWOOD JM; HERBERMAN RB
      COMPARISON OF TOXICITY AND SURVIVAL FOLLOWING INTRAPERITONEAL RECOMBINANT INTERLEUKIN-2 FOR PERSISTENT OVARIAN-CANCER AFTER PLATINUM - 24-HOUR VERSUS 7-DAY INFUSION

      Journal of clinical oncology
    47. KIRKWOOD JM; WILSON J; WHITESIDE TL; DONNELLY S; HERBERMAN RB
      PHASE IB TRIAL AT PICIBANIL (OK-432) AS AN IMMUNOMODULATOR IN PATIENTS WITH RESECTED HIGH-RISK MELANOMA

      Cancer immunology and immunotherapy
    48. DREICER R; PROPERT KJ; KUZEL T; KIRKWOOD JM; ODWYER PJ; LOEHRER PJ
      A PHASE-II TRIAL OF EDATREXATE IN PATIENTS WITH ADVANCED RENAL-CELL CARCINOMA - AN EASTERN-COOPERATIVE-ONCOLOGY-GROUP STUDY

      American journal of clinical oncology
    49. KIRKWOOD JM; LEGHA SS
      ADVANCES IN THE DIAGNOSIS AND TREATMENT OF MALIGNANT-MELANOMA - INTRODUCTION

      Seminars in oncology
    50. KIRKWOOD JM; RESNICK GD; COLE BF
      EFFICACY, SAFETY, AND RISK-BENEFIT ANALYSIS OF ADJUVANT INTERFERON ALFA-2B IN MELANOMA

      Seminars in oncology
    51. KIRKWOOD JM; WAZER D; ROSENSTEIN M
      INTERFERON ADJUVANT THERAPY OF MELANOMA

      Cancer
    52. VINE AK; WILLIS JM; JOHNSON M; MARTONYI C; MCIVER F; SNEED S; STANLEY SA; STERNBERG P; MEREDITH T; BROWN JM; AABERG T; CURTIS L; GILMAN J; CAPONE A; LIM J; SNIPES C; SWORDS R; WARD A; JARRETT WH; AARON J; BAXTER B; HAGLER W; THOMPSON K; SCHACHAT AP; DOLL W; ALEXANDER MF; GREENBERG EF; KAISER S; SACKETT C; TORANO JE; CAIN D; EMMERT D; GEORGE T; GOLDBERG MF; POLLACK L; RICE TA; HARTNETT M; DEMPSEY K; LICHTERMAN S; PRESEREN D; NOVAK MA; ROWE P; SINGERMAN L; ZEGARRA H; TREMPE C; NIES ZF; DUKER J; IMMERMAN R; NASRALLAH F; ODAY T; ROSENBLUM A; WEBER C; WEITER J; JAMPOL LM; PUKLIN J; CHIAPETTA B; DAUBERT G; MANSFIELD M; BEZINOVICH N; CAMPBELL A; GERTY J; GIESE M; MYERS W; PARQUE K; SCHROEDER R; WEINBERG D; GUTMAN FA; ZAKOV N; KISS T; FROBERG D; HARTE B; TANNER V; ABRAM R; AMBLER J; BERLIN L; DALEY G; ROSS D; DAVIDORF FH; TAYLOR C; BILDSTEN J; CORNETET S; CHAMBERS R; CLARK M; SHORTLIDGE G; FULLER D; ANDERSON T; AGUADO H; BRADFORD R; CONWAY D; DALRYMPLE D; EVANS R; FISH GE; NORK C; PICCHIOTTINO R; ROSE K; SNYDER W; STRAACH R; DUTTON JJ; PEDDLE K; HESTON M; LYONS C; SCHUH B; BENETZ BA; SCHIRMER R; RUIZ RS; VARGAS D; DELAGARZA M; JOHNSON R; KOHN W; MAROLA G; TRIPLETT G; HARWOOD H; HORTON T; KELLAWAY J; LAMBERT M; PRAGER T; SHETLAR D; SMITH B; STALLMAN J; WEINGEIST TA; FOUNTAIN C; GRIFFIN M; BLODI C; BOLDT HC; FISHER T; HEFFRON E; OSSOINIG K; STONE E; VERDICK R; WARNER L; MURPHREE AL; LIGGETT P; RYAN SJ; WALONKER AF; PADILLA M; QUILLENTHOMAS B; ALTOMONTE M; DELGADO S; DIDDIE K; FRAMBACH D; GREEN R; JOHNSON J; ROZIER M; SINGER M; TETREAULT G; STRAATSMA BR; CALDWELL R; BARANICK K; HASLOP M; PINAIRE B; ALLEN D; CHUN M; ENGSTROM R; GREENSPAN J; SULIT H; THAYER D; WYNBRANDT L; CHANDRA SR; LEWIS B; BLATZ M; MILLER J; STEWART L; HARRISON R; KNUTSON G; MYERS F; NEIDER M; QUACKENBOSS D; SOMERS G; STEVENS T; FINGER PT; PACKER S; PEARLBERG C; MCCRAY M; TULLER R; MURRAY TG; OLSEN KR; CICCIARELLI N; CASTELLANOS M; DELCALVO M; PEREZ J; SOLER A; ATTAWAY E; DEEN S; HESS D; JARRETT R; KOWAL D; LEWIS ML; LIEBETREU M; NICHOLSON D; RUBSAMEN P; MIELER WF; ABRAMS GW; REKOW SA; HELT P; LEWANDOWSKI M; NAUERTZRITCHIE M; WALTERS J; WIPPLINGER W; ABRAMSON DH; SERVODIDIO CA; BUDINGER K; MARTIN S; ROMANELLAWEIL A; MENDELSOHN M; WILKINS R; WOLFSON R; CHENOWETH RG; IRA S; LEIGH AJ; LORIMER E; ARENDS J; DREYER R; MA CL; RICE P; ZILIS J; WILSON DJ; WATZKE R; CORRADA F; EVANS M; HOLMES D; KLEIN M; FRAUNFELDER F; ROBERTSON J; TALBOT T; ROBERTSON DM; RUSZCZYK MJ; SCHUMANN M; BUETTNER H; LINK T; ROSTVOLD J; MARGHERIO RR; MITCHELL B; CUMMING K; MANATREY P; MCCURLEY S; BRIDGES C; FOX G; MURPHY P; PARK W; SOBEL J; SORENSON D; VERSTRAETEN T; DELPRIORE L; SMITH ME; GAINES M; CLARK L; SCHERRER F; CURTIS R; HART W; SCHATZ H; GUERTIN R; LAUGHLIN K; MILLER A; KELLY M; STOLARCZUK M; SIMPSON ER; FITZPATRICK P; PENNEY L; MACKIE A; CHRISTIANSON M; CONTRACTOR M; EWINGCHOW D; HAMMOND J; JAPP B; KAZDAN M; KODATI SM; MCGOWAN H; MCWHAE J; MIS A; PATON K; PAVLIN C; TANZER H; HAWKINS BS; DIENERWEST M; MOY CS; MARKOWITZ JA; CHURCH RY; BELONGIE CE; COATES TC; CONNOR PB; DAVIS AC; GOLDSBOROUGH IL; GRUBB SC; HARPER DM; JAMES PA; JEFFREYS WS; KEENAN JL; KERMAN JS; MELIA BM; NEWHOUSE MM; OPTICAN DC; BYRNE SF; COMELLA M; MORENO J; SUPERFINERIVERA P; DIBERNARDO C; GENDRON EK; HUGHES JR; MONTAGUE PR; ANDERSON D; SMITH L; STRAUSS J; BENNETT S; FOLK JC; FINE SL; MCCAFFREY L; REICH AM; FATULA E; NIDO V; ALBERT DM; EARLE JD; HANSON WF; KIRKWOOD JM; KURINIJ N; MCCAFFERY L; BRANDON S; GRIZZARD S; MCCORMICK B; MINTURN JT; PAYNE D; SHOFNER JM
      MORTALITY IN PATIENTS WITH SMALL CHOROIDAL MELANOMA - COMS-REPORT-NO-4

      Archives of ophthalmology
    53. RABINOWICH H; BANKS M; REICHERT TE; LOGAN TF; KIRKWOOD JM; WHITESIDE TL
      EXPRESSION AND ACTIVITY OF SIGNALING MOLECULES IN T-LYMPHOCYTES OBTAINED FROM PATIENTS WITH METASTATIC MELANOMA BEFORE AND AFTER INTERLEUKIN-2 THERAPY

      Clinical cancer research
    54. SMITH DC; GERSON SL; LIU LL; DONNELLY S; DAY R; TRUMP DL; KIRKWOOD JM
      CARMUSTINE AND STREPTOZOCIN IN REFRACTORY MELANOMA - AN ATTEMPT AT MODULATION OF O-6-ALKYLGUANINE-DNA-ALKYLTRANSFERASE

      Clinical cancer research
    55. SCHILLER JH; PUGH M; KIRKWOOD JM; KARP D; LARSON M; BORDEN E
      EASTERN COOPERATIVE GROUP TRIAL OF INTERFERON-GAMMA IN METASTATIC MELANOMA - AN INNOVATIVE STUDY DESIGN

      Clinical cancer research
    56. VLOCK DR; ANDERSEN J; KALISH LA; JOHNSON JT; KIRKWOOD JM; WHITESIDE T; HERBERMAN RB; ADAMS GS; OKEN MM; HASELOW RE
      PHASE-II TRIAL OF INTERFERON-ALPHA IN LOCALLY RECURRENT OR METASTATICSQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK - IMMUNOLOGICAL AND CLINICAL CORRELATES

      Journal of immunotherapy with emphasis on tumor immunology
    57. WANG YP; RAO U; MASCARI R; RICHARDS TJ; PANSON AJ; EDINGTON HD; SHIPESPOTLOE JM; DONNELLY SS; KIRKWOOD JM; BECKER D
      MOLECULAR ANALYSIS OF MELANOMA PRECURSOR LESIONS

      Cell growth & differentiation
    58. MAEURER MJ; STORKUS WJ; KIRKWOOD JM; LOTZE MT
      NEW TREATMENT OPTIONS FOR PATIENTS WITH MELANOMA - REVIEW OF MELANOMA-DERIVED T-CELL EPITOPE-BASED PEPTIDE VACCINES

      Melanoma research
    59. COLE BF; GELBER RD; KIRKWOOD JM; GOLDHIRSCH A; BARYLAK E; BORDEN E
      QUALITY-OF-LIFE - ADJUSTED SURVIVAL ANALYSIS OF INTERFERON ALFA-2B ADJUVANT TREATMENT OF HIGH-RISK RESECTED CUTANEOUS MELANOMA - AN EASTERN-COOPERATIVE-ONCOLOGY-GROUP STUDY

      Journal of clinical oncology
    60. KIRKWOOD JM; STRAWDERMAN MH; ERNSTOFF MS; SMITH TJ; BORDEN EC; BLUM RH
      INTERFERON ALFA-2B ADJUVANT THERAPY OF HIGH-RISK RESECTED CUTANEOUS MELANOMA - THE EASTERN-COOPERATIVE-ONCOLOGY-GROUP TRIAL EST 1684

      Journal of clinical oncology
    61. KIRKWOOD JM
      THE DEVELOPMENTAL RATE OF EUPHAUSIA-CRYSTALLOROPHIAS LARVAE IN ELLIS FJORD, VESTFOLD HILLS, ANTARCTICA

      Polar biology
    62. LOGAN TF; GOODING W; KIRKWOOD JM; SHADDUCK RK
      TUMOR-NECROSIS-FACTOR ADMINISTRATION IS ASSOCIATED WITH INCREASED ENDOGENOUS PRODUCTION OF M-CSF AND G-CSF HUT NOT GM-CSF IN HUMAN CANCER-PATIENTS

      Experimental hematology
    63. DOW AI; SHAFER SA; KIRKWOOD JM; MASCARI RA; WAGGONER AS
      AUTOMATIC MULTIPARAMETER FLUORESCENCE IMAGING FOR DETERMINING LYMPHOCYTE PHENOTYPE AND ACTIVATION STATUS IN MELANOMA TISSUE-SECTIONS

      Cytometry
    64. ELKASSAS H; KIRKWOOD JM
      ADJUVANT APPLICATION OF INTERFERONS

      Seminars in oncology
    65. AGARWALA SS; KIRKWOOD JM
      POTENTIAL USES OF INTERFERON ALPHA-2 AS ADJUVANT THERAPY IN CANCER

      Annals of surgical oncology
    66. BROWN ML; CHARRON M; SHAH AN; LISTER J; KIRKWOOD JM; STALTERI MF
      TUMOR IMAGING WITH GA-67-CITRATE - A COST-EFFECTIVE STRATEGY

      Radiology
    67. VLOCK DR; SNYDERMAN CH; JOHNSON JT; MYERS EN; EIBLING DE; RUBIN JS; KIRKWOOD JM; DUTCHER JP; ADAMS GL
      PHASE IB TRIAL OF THE EFFECT OF PERITUMORAL AND INTRANODAL INJECTIONSOF INTERLEUKIN-2 IN PATIENTS WITH ADVANCED SQUAMOUS-CELL CARCINOMA OFTHE HEAD AND NECK - AN EASTERN-COOPERATIVE-ONCOLOGY-GROUP TRIAL

      Journal of immunotherapy with emphasis on tumor immunology
    68. BRADFIELD HA; TAUXE WN; LEVINE G; KIRKWOOD JM; KLEIN H; MOCHIZUKI T
      IN-111 MONOCLONAL-ANTIBODY VERSUS GA-67-CITRATE AND TC-997 SC SUBTRACTION IN A PATIENT WITH MALIGNANT-MELANOMA

      Clinical nuclear medicine
    69. CHANG AY; TU ZN; BRYAN GT; KIRKWOOD JM; OKEN MM; TRUMP DL
      PHASE-II STUDY OF ECHINOMYCIN IN THE TREATMENT OF RENAL-CELL CARCINOMA ECOG STUDY E2885

      Investigational new drugs
    70. LOGAN TF; VIRJI MA; GOODING WE; BONTEMPO FA; ERNSTOFF MS; KIRKWOOD JM
      THE PATHOGENESIS OF DISSEMINATED INTRAVASCULAR COAGULATION IN SEPSIS

      JAMA, the journal of the American Medical Association
    71. AGARWALA SS; KIRKWOOD JM
      INTERFERONS IN THE THERAPY OF SOLID TUMORS

      Oncology
    72. LOGAN TF; SHANNON W; BRYANT J; KANE P; WOLMARK N; POSNER M; KIRKWOOD JM; ERNSTOFF MS; FUTRELL JW; STRAW LD; IWATUSKI S; BAHNSON R
      PREPARATION OF VIABLE TUMOR-CELL VACCINE FROM HUMAN SOLID TUMORS - RELATIONSHIP BETWEEN TUMOR MASS AND CELL YIELD

      Melanoma research
    73. SOMAZA S; KONDZIOLKA D; LUNSFORD LD; KIRKWOOD JM; FLICKINGER JC
      STEREOTAXIC RADIOSURGERY FOR CEREBRAL METASTATIC MELANOMA

      Journal of neurosurgery
    74. ELDER EM; KIRKWOOD JM; WHITESIDE TL
      CHARACTERIZATION OF HUMAN NK CELLS OBTAINED FROM CANCER-PATIENTS AND CULTURED FOR ADOPTIVE IMMUNOTHERAPY

      The Journal of immunology
    75. WHITESIDE TL; LETESSIER E; HIRABAYASHI H; VITOLO D; BRYANT J; BARNES L; SNYDERMAN C; JOHNSON JT; MYERS E; HERBERMAN RB; RUBIN J; KIRKWOOD JM; VLOCK DR
      EVIDENCE FOR LOCAL AND SYSTEMIC ACTIVATION OF IMMUNE CELLS BY PERITUMORAL INJECTIONS OF INTERLEUKIN-2 IN PATIENTS WITH ADVANCED SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK

      Cancer research
    76. WEIDMANN E; LOGAN TF; YASUMURA S; KIRKWOOD JM; TRUCCO M; WHITESIDE TL
      EVIDENCE FOR OLIGOCLONAL T-CELL RESPONSE IN A METASTASIS OF RENAL-CELL CARCINOMA RESPONDING TO VACCINATION WITH AUTOLOGOUS TUMOR-CELLS AND TRANSFER OF IN-VITRO-SENSITIZED VACCINE-DRAINING LYMPH-NODE LYMPHOCYTES

      Cancer research


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/01/21 alle ore 19:37:21